Answers are grounded in this paper and cite their sources.
Preclinical study reveals that G9a-regulated cholesterol biosynthesis triggers cuproptosis in alcohol-related liver disease, highlighting statins and copper chelators as potential therapies.
Whether and how disrupted cholesterol homeostasis contributes to alcohol-related liver disease (ALD) remains elusive. Here, we report that cholesterol biosynthesis is enhanced in ALD livers, driven by a reduction in the H3K9me2 epigenetic landscape orchestrated by the G9a methyltransferase. The heightened cholesterol-associated cuproptotic features, a copper-dependent form of cell death particularly evident in the presence of alcohol, drive extensive liver damage and ALD progression. Notably, pharmacological interventions targeting cholesterol biosynthesis with statins or mitigating cuproptotic features with copper chelators, both clinically available drugs, significantly alleviate disease symptoms in pre-clinical ALD models. In conclusion, our study reveals a previously unrecognized interplay between the G9a epigenetic pathway, hepatic cholesterol metabolism, and alcohol-induced toxicity, establishing cuproptotic features as a key driver of ALD progression. These findings provide a basis for further investigation into modulating cholesterol and copper homeostasis in ALD pathophysiology.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: